ARS Pharmaceuticals (SPRY) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 52.3% versus a loss of 57.8%. Over five years, SPRY leads with a -55.8% price change compared with -67.4% for TECX. Tectonic Therapeutic is the larger company by market cap ($444.0 million vs $433.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRY | TECX |
|---|---|---|
| Share price | $4.36 | $22.71 |
| Market cap | $433.59M | $443.97M |
| 1-day change | +1.51% | +1.34% |
| YTD return | -62.58% | +8.87% |
| 1-year return | -57.79% | +52.31% |
| 5-year return | -55.78% | -67.37% |
| EPS (TTM) | $-2.18 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $39.53 |
| 52-week low | $3.99 | $15.32 |
| Distance from 52-week high | -66.84% | -42.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +416.06% | +237.43% |
| Average volume | 1.86M | 219.12K |
| Shares outstanding | 99.45M | 19.55M |
| Employees | 195 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed SPRY by 110.1 percentage points over the past year.
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
SPRY vs TECX FAQ
Which is bigger, ARS Pharmaceuticals or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $443.97M compared with $433.59M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, SPRY or TECX?
TECX returned +52.31% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are ARS Pharmaceuticals and Tectonic Therapeutic in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ARS Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Tectonic Therapeutic.